[1]Sirvent,JuanA.;Bierer,Donald;Webster,Robert;Lücking,Ulrich[Synthesis,2017,vol.49,#5,p.1024-1036]
[1]Zhang,Guocai;Tan,Hongsheng;Chen,Weichun;Shen,HongC.;Lu,Yue;Zheng,Changwu;Xu,Hongxi[ChemSusChem,2020,vol.13,#5,p.922-928]
[2]Glachet,Thomas;Franck,Xavier;Reboul,Vincent[Synthesis,2019,vol.51,#4,p.971-975]
Title: Scholz A, et al. BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML). [abstract In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3022.
Title: Scholz A, et al. BAY 1143572: A first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, inhibits MYC and shows convincing anti-tumor activity in multiple xenograft models by the induction of apoptosis. [abstract In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr DDT02-02. doi:10.1158/1538-7445.AM2015-DDT02-02
